


## Modified Two-Tier Testing (MTTT) Algorithm for Lyme Disease

In 2019, the FDA cleared several Lyme disease assays with a new indication for use based on a modified two-tier method (MTTT), which was then endorsed by the CDC. In the MTTT, the first-tier test remains unchanged; however, instead of an IgG and/or IgM immunoblot, a different IgG/IgM immunoassay is used for confirmation of positive and equivocal results.<sup>4</sup>

- **Increased Sensitivity** in Early Stage Lyme Disease<sup>5</sup>
- **Definitive** results **faster** as compared to STTT
- Practical advantages such as **lower complexity and cost** compared with Western Blotting



\*Must be FDA-cleared for MTTT indication

1. Branda JA, et al Advances in Serodiagnostic Testing for Lyme Disease Are at Hand, Clinical Infectious Diseases, Volume 66, Issue 7, 1 April 2018, Pages 1133–1139.
2. <https://www.cdc.gov/mmwr/preview/mmwrhtml/00038469.htm>
3. <https://www.cdc.gov/lyme/index.html>
4. Mead P, Petersen J, Hinckley A. Updated CDC Recommendation for Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep. 2019 Aug 16;68(32):703. doi: 10.15585/mmwr.mm6832a4
5. Branda JA, et al Evaluation of Modified 2-Tiered Serodiagnostic Testing Algorithms for Early Lyme Disease. Clin Infect Dis. 2017 Apr 15;64(8):1074-1080. doi: 10.1093/cid/cix043